The dynamics of HER2 status in esophageal adenocarcinoma

Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Creemers, Aafke, Ebbing, Eva A., Hooijer, Gerrit K.J., Stap, Lisanne, Jibodh-Mulder, Rajni A., Gisbertz, Susanne S., van Berge Henegouwen, Mark I., van Montfoort, Maurits L., Hulshof, Maarten C.C.M., Krishnadath, Kausilia K., van Oijen, Martijn G.H., Bijlsma, Maarten F., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6003553/
https://ncbi.nlm.nih.gov/pubmed/29928485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25507
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados